Payload Information
General Information of This Payload
| Payload ID | PAY0JTEXX |
|||||
|---|---|---|---|---|---|---|
| Name | PBD |
|||||
| Synonyms |
PBD
Click to Show/Hide
|
|||||
| Target | Deoxyribonucleic acid (DNA) | |||||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
wO2024181570A1 ADC7 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
10 ng/mL
|
Negative CD138 expression (CD138-) | ||
| Method Description |
1000 cells/well of Jurkat in 96 well, 37 °C for 5 days.
|
||||
| In Vitro Model | T acute lymphoblastic leukemia | Jurkat cells | CVCL_0065 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
20 ng/mL
|
Positive CD138 expression (CD138+++/++) | ||
| Method Description |
1000 cells/well of Capan-1 in 96 well, 37 °C for 5 days.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | Capan-1 cells | CVCL_0237 | ||
AbA_D265C_LALA_IHH-PBD [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) |
0.0294 nM
|
Positive CD34+,CD90+ expression (CD34+,CD90+ +++/++) | ||
| Method Description |
In vitro BM HSC killing assay: ADCs conjugated to AM1 or PBD
|
||||
| In Vitro Model | Bone marrow hematopoietic stem cells | BM HSC cells (CD34+CD90+) | Homo sapiens | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) |
0.042 nM
|
Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro cell line killing assays
|
||||
| In Vitro Model | B acute lymphoblastic leukemia | Reh cells | CVCL_1650 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) |
0.36 nM
|
Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro cell line killing assays
|
||||
| In Vitro Model | T acute lymphoblastic leukemia | Jurkat cells | CVCL_0065 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) |
0.8185 nM
|
Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro cell line killing assays
|
||||
| In Vitro Model | Adult acute myeloid leukemia | SKNO-1 cells | CVCL_2196 | ||
IN202417103159A 2188-D04-Yl80-LP9 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.0003 nM
|
Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
|
||||
| In Vitro Model | Embryonal carcinoma | Ntera-2 cells | CVCL_0034 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 10 nM | Negative ROR1 expression (ROR1-) | ||
| Method Description |
The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
|
||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
References